Teaching Objectives Describe the balance a that must be sought in the treatment of pain and the prevention of drug diversion. Discuss regulatory polic

Similar documents
KANSAS Kansas State Board of Healing Arts. Source: Kansas State Board of Healing Arts. Approved: October 17, 1998

Dear DEA. Howard A. Heit, MD, FACP, FASAM,* Edward Covington, MD, and Patricia M. Good

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

California. Prescribing and Dispensing Profile. Research current through November 2015.

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Vermont. Prescribing and Dispensing Profile. Research current through November 2015.

Guideline for the Rational Use of Controlled Drugs

Rule Governing the Prescribing of Opioids for Pain

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Oklahoma. Prescribing and Dispensing Profile. Research current through November 2015.

West Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Patient Agreement for the use of Opioid Medications

ASPMN Conference Baltimore, Maryland

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition)

Colorado State Board of Medical Examiners Policy

FEDERAL & STATE LAWS RELATED TO THE PRESCRIBING OF CONTROLLED SUBSTANCES LEONARD SCHUCHMAN, DO, MPH, FAAFP PRESIDENT- ELECT, NJAOPS

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

Rhode Island. Prescribing and Dispensing Profile. Research current through November 2015.

RULES OF THE ALABAMA STATE BOARD OF MEDICAL EXAMINERS

Minnesota. Prescribing and Dispensing Profile. Research current through November 2015.

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System

SECTION PRESCRIPTIONS

Controlled Substance Prescribing and Diversion. Pamela Polk, R. Ph., Inspector DHEC Bureau of Drug Control

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

WHAT YOU NEED TO KNOW TO ABOUT AB 474

OCCUPATIONAL AND PROFESSIONAL LICENSING MEDICINE AND SURGERY PRACTITIONERS MANAGEMENT OF PAIN AND OTHER CONDITIONS WITH CONTROLLED SUBSTANCES

MEDICATION MANAGEMENT AGREEMENT

Utah. Prescribing and Dispensing Profile. Research current through November 2015.

INFORMED CONSENT FOR OPIOID TREATMENT FOR NON-CANCER/CANCER PAIN Texas Pain and Regenerative Medicine

DEA: Combating the Supply

New Mexico. Prescribing and Dispensing Profile. Research current through November 2015.

Readopt with amendment Med 502, effective (Document #11090), to read as follows:

ISSUING AGENCY: Regulation and Licensing Department - NM Board of Osteopathic Medical Examiners.

Revised Appendix E of the Code of Professional Conduct promulgated in Issue No. 24 of the newsletter of the Medical Council in December 2017

Prescription Monitoring Program (PMP)

Opioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

Within the Scope of Practice/Role of _X APRN RN LPN CNA ADVISORY OPINION PAIN MANAGEMENT GUIDELIINES

9/5/2011. Outline. 1. Past and Current Trends re: RX Abuse 2. Diversion Methods 3. Regulatory Reporting Requirements 4. Q/A

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Appendix F Federation of State Medical Boards

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

Managing Risks Associated with Doctor Shopping and Other Drug-Seeking Behaviors

The CARA & Buprenorphine Prescribing for APNs & PAs

Our Journey to Addressing the PA PDMP Program. Dean Parry, RPh AVP Clinical Informatics, Care Support Services Geisinger Health System

Proposed Revision to Med (i)

Reference for Physicians on the Use of Opioid Analgesics in the Treatment of Chronic Pain, in the Office Setting

MEDICATION MANAGEMENT AGREEMENT Pain Management Program Participation Agreement and Consent

Legal Issues in Opioid Prescribing

Ahsan U. Rashid, M.D., F.A.C.P.

Prepublication Requirements

Do not open the test booklet prior to being told to do so.

North Carolina, like the rest of the nation, has been experiencing

Pennsylvania Prescription Drug Monitoring Program Trends,

Michigan Opioid Legislation Hospital Compliance Checklist

Risk Evaluation And Mitigation Strategies:

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

9/13/2017 DEA WHO WE ARE: Prescription Drug Abuse. American Association of Service Coordinators September 24-27, 2017 Disney s Coronado Springs Resort

OPIOID PAIN MEDICATION Agreement and Informed Consent

Aniston's 'Cake' shines a light on Rx drug abuse epidemic

Prescription Drug Monitor Programs (PMDP): Combating prescription drug misuse and abuse. A physician s perspective.

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

Medicare Advantage Outreach and Education Bulletin

The Role of the PDMP: Foundational Knowledge and Best Practices

MQAC Rules for the Management of Chronic Non-Cancer Pain For Allopathic Physicians Effective January 2, 2012

Sample Street Prices*

Role of PMPs in Preventing Substance Abuse National Conference of State Legislatures December 6, 2006 San Antonio, Tx

The Role of Dentists in Preventing Opioid Abuse Tufts Health Care Institute Program on Opioid Risk Management 12 th Summit Meeting March 11-12, 2010

Attitudes Toward Medication-Assisted Treatment Within a Drug Court Program. Caroline Allison. Dr. Kathleen Moore, Ph.D.

Ontario s Narcotics Strategy

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program

Comments on the proposal may be submitted to Colleen Klein, P.O. Box 2018, Austin, Texas A public hearing will be held at a later date.

25/04/2017. To ensure that the Rx meets CPSS standards. To provide patient-centered, individualized care. To safely dispense the patient s medication

Standard of Practice for Prescribing Opioids (Excluding Cancer, Palliative, and End-of-Life Care)

NBPDP Drug Utilization Review Process Update

Prescribing Controlled Substances and the PDMP

Methadone Maintenance 101

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

Our Core Thoughts on Dealing with the Opioid Addiction Crisis. Meghan McNelly, PharmD, MHA, FACHE Suzette Song, MD Joseph Alhadeff, MD

State, District, or Territory Criteria for Mandatory Enrol ment or Query of PDMP

11/11/2015. MVAs Suicide Firearms Homicide. Where Can I Find A Copy of the PDMP Law? Why Was the Law Established? Why Was the Law Established?

THE FDA DRUG APPROVAL PROCESS Under the Federal Food, Drug, and Cosmetic (FD&C) Act, FDA is responsible for ensuring that all new drugs are safe and

Brief History of Methadone Maintenance Treatment

Policy Title. Control Number HR003. Exception The Scotland County Sheriff s Department is subject to a separate policy.

Update on the Opioid Crisis

Managing the Drug-Free Workplace Quiz

Liability, Informed Consent, and Risk Management 15 Thoughts for Pain Management Physicians

Prescription Opioid Overdose in Oregon: A public health perspective

Drug and Alcohol Policy

EMERGENCY DEPARTMENT MODEL PRACTICES DEALING WITH THE PRESCRIPTION OPIOID EPIDEMIC

About this consent form

Mark W. Caverly, Chief Liaison and Policy Section

Opioid Crisis, Our Response Massachusetts Coalition for the Prevention of Medical Errors. October 31, 2016

Using CURES to combat prescription drug abuse/misuse

Approved Procedures for Prescribing and Monitoring Controlled Substances in South Carolina

Review of Controlled Drugs and Substances Act

Chronic Pain Management in the Primary Care Setting

Transcription:

Preventing Controlled Substance Diversion David B. Brushwood, R.Ph.,., J.D. Professor of Pharmaceutical Outcomes & Policy The University of Florida

Teaching Objectives Describe the balance a that must be sought in the treatment of pain and the prevention of drug diversion. Discuss regulatory policy in the prescribing and dispensing of opioid analgesics. List the factors that correlate with regulatory problems for health care providers who use opioids in the treatment of chronic pain. Describe strategies to avoid regulatory problems in the provision of opioids to chronic pain patients.

The Drug Problem in America Inthe45to54agegroup to 54 group, overdose deaths from Rx drugs now surpass motor vehicle accidents as the #1 cause of accidental death. Nearly 7 million Americans abuse Rx drugs. 1i in 5t teenagers has abused dr Rx pain medications.

America s Other Drug Problem Undertreatment of pain is a serious problem in the United States, including pain among patients with chronic conditions and those who are critically ill or near death. Pain is undertreated in nearly half of all patients with cancer. 15% of children experience chronic pain; it can have long-lasting lasting effects on social, emotional & physical development.

There Is A Storm Coming Patients in pain want their medications and they don t want hassles. Abuse of Prescription Medications is Increasing. Drug Diverters Target Pharmacies. The Failure to Prevent Diversion Will Attract Regulatory Attention. Regulators May Confuse Successful Practice With Diversion. Prescribers and Pharmacists Share concerns.

The Structure of CS Law Controlling Substances Scheduling of drugs Registration of those who may control drugs Rules for distribution and control Record keeping from cradle to grave There is a closed system of distribution for drugs with abuse potential. Is there a closed system of distribution for drugs with abuse potential? Medications intended for use in healing are diverted to illicit purposes. Diversion and abuse cause human suffering. Drug regulators have emphasized the need to reduce diversion i and resulting abuse. How does diversion occur? Who is responsible for diversion?

Sources of Diversion Medical Sources Health Care Professionals Duped Dishonest Disabled Dated This is primarily a health care system problem. Nonmedical Sources Robbery Hijacking Burglary Employee Pilferage Patient Leakage Importation The Internet t This is primarily a law enforcement problem.

The Practitioner s Dilemma The Therapeutic Imperative: Always provide opioid analgesics, and other controlled substances, when they are appropriate for a patient. Help the patients who need help. The Regulatory Imperative: Never provide opioid analgesics when they are inappropriate for a patient. Push the pushers out of the pharmacy. To be successful, these two imperatives must be balanced with each other. Do not permit one to be emphasized over the other.

Good and Bad Decisions What is our Dirty Little Secret? HCP Atiit Activity Prescribed/ Dispensed State of the World Patient Is Patient NOT Legitimate Legitimate Pain Patient* Pain Patient Opioids are Good Bad Decision Opioids NOT Prescribed/ Dispensed Bad Decision Bad Decision Good Decision *Assume that opioids are appropriate therapy for the patient.

Bad Decisions Cannot Be Eliminated HCP Atiit Activity Prescribed/ Dispensed State of the World Patient Is Patient NOT Legitimate Legitimate Pain Patient* Pain Patient Opioids are Good Bad Decision Opioids NOT Prescribed/ Dispensed Bad Decision Bad Decision Good Decision *Assume that opioids are appropriate therapy for the patient.

Using Balance to Reduce Bad Decisions HCP Atiit Activity State of the World Patient Is Legitimate Pain Patient* Opioids are Good Bad Prescribed/ Dispensed Opioids NOT Prescribed/ Decision Bad Patient NOT Legitimate Pain Patient Decision Good Decision Decision Dispensed *Assume that opioids are appropriate therapy for the patient.

Important Distinctions Addiction is a disease state. Drug abuse is the intentional use of drugs for a purpose other than a therapeutic purpose. Aberrant behaviors Sharing drugs Unauthorized increase in dose Unauthorized route of administration Reference: Passik, Commentary. Pain Medicine, 8: 442-4545 (2007).

FSMB Pain Mgt. Guidelines Addiction - a neurobehavioral syndrome with genetic and environmental influences that results in psychological dependence on the use of substances for their psychic effects and is characterized by compulsive use despite harm. Physical dependence and tolerance are normal physiological consequences of extended opioid therapy for pain and should not be considered addiction.

FSMB Pain Mgt. Guidelines Tolerance - the need to increase the dose of opioid to achieve the same level of analgesia. does not equate with addiction Physical Dependence - physiologic state of neuro- adaptation characterized by emergence of withdrawal syndrome if drug use is stopped or decreased abruptly. does not equate with addiction. Pseudoaddiction - pattern of drug-seeking behavior of pain patients who are receiving inadequate pain management and can be mistaken for addiction

FSMB Pain Mgt. Guidelines Evaluation Consultation complete history and physical exam documented d Treatment Plan therapeutic goals, further evaluations Informed Consent Periodic Review reasonable intervals refer if necessary Medical Records complete and accurate Compliance with Controlled Substance Laws

The Ambiguity of Red Flags Flag Regulators Health Care Professionals Pts. Come from miles away Multiple symptoms treated A Candy Store Polypharmacy Specialty practice Holistic care High Doses No medical need Individualized care Lethal Pt. Asks for drugs by Addiction Pt. accepting name responsibility Returns too early Dealing Crisis

DEA Regulations A Setup For Forensic Challenges 21 CFR 1306.04 Purpose of Issue of Prescription (a) A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an individual practitioner acting in the usual course of his professional practice.. The responsibility for the proper prescribing and dispensing of controlled substances is upon the prescribing practitioner, but a corresponding responsibility rests with the pharmacist who fills the prescription. p An order purporting p to be a prescription p issued not in the usual course of professional treatment or in legitimate and authorized research is not a prescription and the person knowingly filling such a purported prescription, as well as the person issuing i it, shall be subject to the penalties provided for violations of the law.

DEA Compliance Advice to Pharmacists Pharmacist s Guide to Prescription Fraud Characteristics of Forged Prescriptions 1. Prescription looks too good ; the prescriber s handwriting is too legible 2. Quantities, directions or dosages differ from usual medical usage 3. Prescription does not comply with the acceptable standard abbreviations or appears to be textbook presentations 4. Prescription appears to be photocopied 5. Directions written in full with no abbreviations

The VIGIL Process Verification f Unnecessary if you know a patient s need is valid. Identification Generalization Interpretation Legalization Not useful if you know a patient s need is invalid. For those in between situations, to become comfortable. The Traditional Advice As long as you practice good The Traditional Advice, As long as you practice good pharmacy and document thoroughly you ll be OK, is simply not true. Good clinical practice is necessary, but it is not sufficient. It may get you out of trouble once you are in it, but it will not keep you out of trouble to begin with.

The Purpose of VIGIL Restoring a policy of Balance to practice. Screening out non-patients who traffic in drugs. Reminding actual patients that they have responsibilities if medication use. Demonstrating Good Faith in prescribing and dispensing.

Verification Is this a responsible opioid user? Prescriber Talk with the patient openly about prior use Do not prescribe high dose C-II opioid or hydrocodone/acetaminophen as first treatment of pain without verifying prior use with previous prescriber Alternative is trusted colleague who may vouch for patient Define success with therapy Be open to verification requests of pharmacist Pharmacist Call for verification the first time a prescription is presented Document the purpose of the medication Notify the prescriber if anything unusual happens

Identification Do I know for sure who this person is? Prescriber and Pharmacist Require government issued photo ID of anyone being prescribed or picking up Rx for C-II opioids or hydrocodone/acetaminophen This includes patient or family member Photocopy ID or write down information Reasonable substitute is ok if circumstances warrant

Generalization Do we agree on mutual responsibilities Prescriber and expectations? I am your health care provider and I agree to promptly and respectfully provide medications and services if rules are met Possible rules (but you decide what fits): Keep all controlled substances under lock & key No sharing drugs with anyone If more than 20% too early, call me to explain Present Rxs for new drugs during business hours No emergency refills when there is no emergency It is your responsibility to know when you will run out. Your choice, but use only one pharmacy for CS drugs Put this in writing if necessary Pharmacist Know the rules and remind patients t of them Report infractions to the prescriber

Interpretation Do I now feel comfortable allowing this person to have controlled substances? Prescriber Contact another prescriber or pharmacist for support with hypothetical question Use brief questionnaire to predict misuse or abuse by yp patient Drug Abuse Screening Test (DAST) Opioid Risk Tool (ORT) Screener and Opioid Assessment for Patients t in Pain (SOAPP) Require a diary and obtain family or friend feedback regarding patient functioning Pharmacist Consult with prescriber (not the police) as needed d regarding patient behaviors Be alert for activities of concern Resolve all third party pay questions days supply, etc.

Legalization How can I stay squeaky clean in meeting my legal requirements? Prescriber Follow state and federal laws for CS, with NO exceptions Be familiar with State Medical Board regulations, and follow them Document what you have done but with care. Notes should be objective and avoid pejorative comments Follow up on concerns that have been documented re drug use or possible addiction Pharmacist Take a medication history Educate the patient and provide pertinent literature Physical dependence vs. addiction Tapering vs. detoxification Follow up on all Drug Use Review edits

Schedule II Prescriptions Must be in writing, except No Refills, but Partial filling ok emergency situation Outpatient; must fill balance verbal ok within 72 hours quantity limited to Time for verification. emergency LTCF or terminal illness pharmacist reduces to writing Must fill balance within 60 days within 7 days, prescriber sends written Rx Must record each partial facsimile ok as original if filling Narcotic & infusion therapy There is no specific time period Resident of LTCF within which a C-II prescription must be filled. (Federal Law). Narcotic & patient enrolled Texas is 7 days. NJ is 30 days. Must be in writing, except in hospice care

Multiple C-II Prescriptions An individual practitioner (IP) may issue multiple prescriptions authorizing the patient to receive a total of up to a 90-day supply of a C-II CS. The IP must conclude that providing the patient with multiple prescriptions in this manner does not create an undue risk of diversion or abuse. IPs must determine on their own, based on sound medical judgment, and in accordance with established medical standards,, whether it is appropriate to issue multiple prescriptions.

Schedule II cont. Pharmacist Changes on a CS Rx Prescribing for Maintenance or OK: dosage form, strength, Detoxification i not Legal-- --OTP only quantity, directions, date. When referring to OTP, NOT OK: Patient s name, drug to 3 days; Hospital ok when (except generic), prescriber s admitted d for other reason. signature. Buprenorphine: C-II currently in question. This /subutex_suboxone/default.htm results from a pharmacy Prescribing for addicts in pain is newsletter query. legal. Methadone for pain is perfectly If releasing a patient, prescribing fine. final supply, and verbally specify No restrictions--other than tapered dose (if no diversion). those for all C-II. Tapering opioids is not Not required, but good practice detoxification. to write for pain. administer one day at time, up www.fda.gov/cder/drug/infopage

Forms for VIGIL Medication Use Agreement Pharmacy Responsibilities Patient Responsibilities Relative/Close Friend Patient Questionnaire Live w >2 people? >one prescriber/mo? Generics okay? Pharm Care Assessment Legal res of county? Pay cash? Male? Between 16 & 45? Non-CS in past 6 mo? Documentation Steps Rx Stickers

Responsibilities in VIGIL Prescriber Patient Pharmacist Clarify Practice Rules Supervise Staff Respond d to R.Ph. Queries Be Active in the Profession Prescribe Needed Meds Be Open and Honest Accept and Follow the Rules Control Access to Drugs Plan Ahead Contact Prescribers with Concerns Be Informed on Pain Management Avoid Bias Dispense Needed Meds